文献速递青光眼

全身合并症对青光眼用药依从性的长期影响

Long-Term Effect of Systemic Comorbidity on Glaucoma Medication Adherence.
PubMed 文献 · Am J Ophthalmol · 2024-01-24

本研究基于台湾全民健康保险申报数据,纳入50408例新诊断青光眼患者并随访5年,发现至少1种合并症者在青光眼发病后前2年用药持有率较高,但第4、5年下降,且合并症数量越多不依从程度越高,≥4种合并症者第4、5年用药依从性分别降低6.4%(P=0.033)和11.8%(P<0.001)。

要点

  • 至少1种合并症者青光眼发病后前2年用药持有率高于无合并症者。
  • 合并症者用药持有率在发病第4、5年下降。
  • ≥4种合并症者第4、5年用药依从性分别降低6.4%(P=0.033)和11.8%(P<0.001)。

核心结论

  • 合并症的存在可使青光眼用药依从性在长期内降低最多12%。
  • 合并症越多可能增加慢性病管理负担,因青光眼无明显症状,其治疗可能未获优先。

研究设计与样本

  • 队列研究,基于台湾全民健康保险申报数据,纳入2011年1月1日至2020年12月31日期间新诊断青光眼并随访5年的患者。
  • 共纳入50408例确诊新诊断青光眼患者。
  • 使用Deyo-Charlson合并症指数识别合并症,以药物持有率(MPR)衡量依从性,MPR为患者有青光眼药物供应的总天数除以365。

主要发现

  • 与无合并症患者相比,至少1种合并症患者在青光眼发病后前2年MPR较高。
  • 至少1种合并症患者的MPR在长期下降,具体在发病后第4年和第5年。
  • 不依从程度随合并症数量增加而增加。
  • ≥4种合并症患者青光眼用药依从性显著降低,发病后第4年降低6.4%(P=0.033),第5年降低11.8%(P<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether systemic comorbidity is associated with reduced adherence to glaucoma medication and whether this decrease varies according to the number of comorbidity and the time after glaucoma onset. DESIGN: Cohort study. METHODS: Setting: Population-based. STUDY POPULATION: All patients with confirmed newly diagnosed glaucoma in one or both eyes were identified using National Health Insurance (NHI) claims data from Taiwan. OBSERVATION PROCEDURE: Individuals with newly diagnosed glaucoma were followed up for 5 years from onset. The study period was from January 1, 2011, to December, 31, 2020. Patient comorbidities were identified using the Deyo-Charlson Comorbidity Index. Adherence was measured using the medication possession ratio (MPR). The MPR was calculated by dividing the total number of days a patient had a supply of glaucoma medication by 365. Data for the MPR were extracted from NHI outpatient and drug records. RESULTS: This study included a total of 50 408 patients. Compared with patients without comorbidity, patients with at least 1 comorbidity exhibited higher MPR in the first 2 years following glaucoma onset. However, their MPR decreased in the long term, specifically in the fourth and fifth years after onset. Additionally, the degree of nonadherence increased with the number of comorbidities. Patients with ≥4 comorbidities had significantly lower glaucoma medication adherence, with reductions of 6.4% (P = .033) and 11.8% (P < .001) in the fourth and fifth years after glaucoma onset, respectively. CONCLUSION: The presence of comorbidity can reduce glaucoma medication adherence by up to 12% in the long term. More comorbidities may increase the burden of managing chronic diseases; as a result, treatment for glaucoma may not receive priority due to the absence of clear symptoms of the condition.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hou CH, Pu C. Long-Term Effect of Systemic Comorbidity on Glaucoma Medication Adherence. Am J Ophthalmol. 2024. PMID: 38278203. doi:10.1016/j.ajo.2024.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。